Steven currently is a senior full professor of health economics at KU Leuven. His research and teaching interests focus on health economic aspects of medicinal products, including economic evaluations, budget impact analyses, market access policies and incentives. He has a particular interest in oncology medicines, orphan medicines, biologics and biosimilars, vaccines, antibiotics, cell and gene therapies.

He is one of the founders of the ‘Market analysis of biologics and biosimilars following loss of exclusivity’ (MABEL) Fund (https://gbiomed.kuleuven.be/english/research/50000715/52577001/mabel) and of the ‘Personalised medicine strategies’ (PROMISE) Fund (https://gbiomed.kuleuven.be/english/research/50000715/52577001/promise) at KU Leuven.

Steven is the (co-)author of 350 publications in peer-reviewed journals (see full list at https://lirias.kuleuven.be/cv?u=U0043289). He has been recognised by Expertscape as one of the top 1% of scholars worldwide writing about Reimbursement Health Insurance from 2011 through 2021.